Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02.
Leleu X et al. Blood. 2015 Jan 9. pii: blood-2014-11-612069. [Epub ahead of print].

The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution.
Puig N et al. Leukemia. 2015 Jan 8. doi: 10.1038/leu.2015.7. [Epub ahead of print].

Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
Jing W et al. J Immunother Cancer. 2015 Jan 20;3(1):2. doi: 10.1186/s40425-014-0043-z. eCollection 2015.

TM-233, a novel analog of ACA, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M et al. Cancer Sci. 2015 Jan 23. doi: 10.1111/cas.12616. [Epub ahead of print].

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.
Fionda C et al. BMC Cancer. 2015 Jan 22;15(1):17. [Epub ahead of print].

Association of antigen-specific T-cell responses with antigen-expression and immunoparalysis in multiple myeloma.
Fichtner S et al. Clin Cancer Res. 2015 Jan 21. pii: clincanres.1618.2014. [Epub ahead of print].

Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance inmultiple myeloma.
Abdel Malek MA et al. Oncotarget. 2014 Dec 26. [Epub ahead of print].

Characterization of a new human plasma cell leukemia cell line UHKT-944.
Vyhlídalová I et al. Eur J Haematol. 2015 Jan 20. doi: 10.1111/ejh.12505. [Epub ahead of print].

Crystal Structure of the Human 20S Proteasome in Complex with Carfilzomib.
Harshbarger W et al. Structure. 2015 Jan 14. pii: S0969-2126(14)00411-0. doi: 10.1016/j.str.2014.11.017. [Epub ahead of print].

The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors.
Wang HL et al. Bioorg Med Chem Lett. 2014 Dec 30. pii: S0960-894X(14)01376-6. doi: 10.1016/j.bmcl.2014.12.068. [Epub ahead of print].

Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions in various clinical materials of myeloma patients.
Sata H et al. Exp Hematol. 2015 Jan 12. pii: S0301-472X(15)00006-5. doi: 10.1016/j.exphem.2015.01.002. [Epub ahead of print].

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax).
Leverson JD et al. Cell Death Dis. 2015 Jan 15;6:e1590. doi: 10.1038/cddis.2014.561.

Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma.
Yang Y et al. Cancer Res. 2015 Jan 14. [Epub ahead of print].

Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice.
Alé A et al. Neurotox Res. 2015 Jan 15. [Epub ahead of print].

Tyrosine phosphorylation of the Lyn SH2 domain modulates its binding affinity and specificity.
Jin LL et al. Mol Cell Proteomics. 2015 Jan 13. pii: mcp.M114.044404. [Epub ahead of print].

Concomitant bone marrow involvement by plasma cell myeloma and primary myelodysplastic syndrome with biclonal complex chromosome anomalies.
Nanaji NM et al. Leuk Lymphoma. 2015 Jan 14:1-7. [Epub ahead of print].

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.
Smith D et al. Br J Haematol. 2015 Jan 12. doi: 10.1111/bjh.13258. [Epub ahead of print].

Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells. Part II: Impact of latent cytomegalovirus infection and catecholamine sensitivity.
Bigley AB et al. Brain Behav Immun. 2015 Jan 9. pii: S0889-1591(15)00002-1. doi: 10.1016/j.bbi.2014.12.027. [Epub ahead of print].

Immunohistochemical expression of cell cycle proteins in multiple myeloma.
Pessach I et al. Leuk Lymphoma. 2015 Jan 9:1-12. [Epub ahead of print].

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.
Murray MY et al. Cell Cycle. 2015 Jan 7:0. [Epub ahead of print].

The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment.
Jurczyszyn A et al. J Cancer. 2015 Jan 5;6(2):160-8. doi: 10.7150/jca.10873. eCollection 2015.

Alkylating Agent Melphalan Augments the Efficacy of Adoptive Immunotherapy Using Tumor-Specific CD4+ T Cells.
Lu X et al. J Immunol. 2015 Jan 5. pii: 1401894. [Epub ahead of print].

Population Pharmacokinetics of Pomalidomide.
Li Y et al. J Clin Pharmacol. 2015 Jan 3. doi: 10.1002/jcph.455. [Epub ahead of print].

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.
Greenberg AJ et al. Blood Cancer J. 2015 Jan 2;4:e271. doi: 10.1038/bcj.2014.91.

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA Approved Ritonavir and Metformin.
Dalva-Aydemir S et al. Clin Cancer Res. 2014 Dec 26. pii: clincanres.1088.2014. [Epub ahead of print].

Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function.
Qi C et al. Cancer Invest. 2015 Jan;33(1):6-15. doi: 10.3109/07357907.2014.988340.

Protein ubiquitination in lymphoid malignancies.
Yang Y et al. Immunol Rev. 2015 Jan;263(1):240-56. doi: 10.1111/imr.12247.

Targeting the bone marrow microenvironment in multiple myeloma.
Kawano Y et al. Immunol Rev. 2015 Jan;263(1):160-72. doi: 10.1111/imr.12233.

LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.
Brunetti G et al. Oncotarget. 2014 Dec 30;5(24):12950-67.

Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
Szmania S et al. J Immunother. 2015 Jan;38(1):24-36. doi: 10.1097/CJI.0000000000000059.

AKT as locus of cancer phenotype.
Radisavljevic Z et al. J Cell Biochem. 2015 Jan;116(1):1-5. doi: 10.1002/jcb.24947.

Identify multiple myeloma stem cells: Utopia?
Saltarella I et al. World J Stem Cells. 2015 Jan 26;7(1):84-95. doi: 10.4252/wjsc.v7.i1.84.

A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts.
Matsushita M et al. PLoS One. 2015 Jan 24;10(1):e0116135. doi: 10.1371/journal.pone.0116135. eCollection 2015.